Key result
Prolonged immunosuppression linked to rare de novo angiosarcoma at a functioning renal allograft site.
Why the study?
De novo angiosarcoma in the post-transplant population is extremely rare and requires further clinical awareness and management strategies.
Case Report (n=1)
This case underscores the importance of periodic surveillance for the development of malignancy in the immunosuppressed post-transplant population.
Alerts clinicians to rare de novo angiosarcoma in functioning renal allografts; leaves open whether intensified surveillance alters outcomes in transplant recipients.
Prolonged exposure to immunosuppressive medication is a known risk factor for the development of post-transplant malignancies. De novo angiosarcoma in the post-transplant population is extremely rare. We present an 81-year-old female who developed an angiosarcoma at the site of a functioning renal allograft and review contemporary treatment strategies for this devastating disease. The report underscores the importance of periodic surveillance for the development of malignancy in the immunosuppressed population.
No takes yet. Share an insight, caveat, or question.
Ferroni et al. (2014) conducted a case report in De novo angiosarcoma of a renal allograft (n=1). Immunosuppressive medication was evaluated on Development of angiosarcoma. An 81-year-old female developed an extremely rare de novo angiosarcoma at the site of a functioning renal allograft following prolonged exposure to immunosuppressive medication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: